Tirdzniecība Arcturus Therapeutics Holdings Inc. - ARCT CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.09 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 15.04 |
| Atvērt* | 14.51 |
| Izmaiņas par 1 gadu* | -58.88% |
| Dienas Diapazons* | 14.51 - 15.59 |
| 52 ned Diapazons | 11.70-31.41 |
| Vidējais apjoms (10 dienas) | 318.14K |
| Vidējais apjoms (3 mēneši) | 6.86M |
| Tirgus Kapitalizācija | 400.04M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 26.49M |
| Ieņēmumi | 51.50M |
| EPS | -5.56 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 2.56 |
| Nākamās Peļņas Datums | Mar 28, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 15.37 | 0.54 | 3.64% | 14.83 | 15.60 | 14.44 |
| Jun 28, 2022 | 15.04 | -0.93 | -5.82% | 15.97 | 16.21 | 14.77 |
| Jun 27, 2022 | 16.14 | 0.75 | 4.87% | 15.39 | 16.39 | 15.22 |
| Jun 24, 2022 | 15.87 | -0.21 | -1.31% | 16.08 | 16.42 | 14.99 |
| Jun 23, 2022 | 15.93 | 0.85 | 5.64% | 15.08 | 16.08 | 14.88 |
| Jun 22, 2022 | 15.36 | 1.52 | 10.98% | 13.84 | 16.06 | 13.84 |
| Jun 21, 2022 | 14.51 | 0.68 | 4.92% | 13.83 | 15.47 | 13.83 |
| Jun 17, 2022 | 13.39 | 0.89 | 7.12% | 12.50 | 14.16 | 12.50 |
| Jun 16, 2022 | 12.21 | -0.26 | -2.09% | 12.47 | 12.63 | 11.65 |
| Jun 15, 2022 | 13.22 | 0.38 | 2.96% | 12.84 | 13.45 | 12.27 |
| Jun 14, 2022 | 12.85 | -0.43 | -3.24% | 13.28 | 13.28 | 12.31 |
| Jun 13, 2022 | 13.13 | -1.10 | -7.73% | 14.23 | 14.23 | 12.47 |
| Jun 10, 2022 | 15.03 | -1.42 | -8.63% | 16.45 | 16.75 | 14.66 |
| Jun 9, 2022 | 17.07 | -1.92 | -10.11% | 18.99 | 18.99 | 16.99 |
| Jun 8, 2022 | 19.40 | 0.14 | 0.73% | 19.26 | 20.15 | 19.17 |
| Jun 7, 2022 | 19.43 | 1.48 | 8.25% | 17.95 | 19.56 | 17.74 |
| Jun 6, 2022 | 18.46 | -1.51 | -7.56% | 19.97 | 20.59 | 17.57 |
| Jun 3, 2022 | 19.89 | 1.99 | 11.12% | 17.90 | 19.94 | 17.90 |
| Jun 2, 2022 | 18.77 | 1.00 | 5.63% | 17.77 | 19.11 | 17.77 |
| Jun 1, 2022 | 18.37 | -0.88 | -4.57% | 19.25 | 20.51 | 17.93 |
Arcturus Therapeutics Holdings Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 12.359 | 9.539 | 20.789 | 15.753 | 12.998 |
| Ienākumi | 12.359 | 9.539 | 20.789 | 15.753 | 12.998 |
| Kopējie Darbības Izdevumi | 215.211 | 81.063 | 46.302 | 37.564 | 23.49 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 41.451 | 23.217 | 12.662 | 20.582 | 7.572 |
| Pētniecība un Attīstība | 173.76 | 57.846 | 33.64 | 16.982 | 15.918 |
| Darbības Izdevumi | -202.852 | -71.524 | -25.513 | -21.811 | -10.492 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.822 | -0.624 | -0.478 | 0.026 | -0.061 |
| Citi, Neto | 0 | -0.348 | |||
| Neto Ienākumi Pirms Nodokļu Nomaksas | -203.674 | -72.148 | -25.991 | -21.785 | -10.901 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Neto Ienākumi | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Atšķaidītie Neto Ienākumi | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Atšķaidītie Ienākumi par Akcijām | 26.317 | 20.305 | 12.069 | 10.069 | 3.087 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -7.73926 | -3.55321 | -2.15353 | -2.16357 | -3.53158 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -7.73926 | -3.55321 | -2.15353 | -2.16357 | -3.53158 |
| Ārkārtas Posteņi Kopā | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 5.244 | 5.794 | 2.437 | 2.001 | 2.127 |
| Ienākumi | 5.244 | 5.794 | 2.437 | 2.001 | 2.127 |
| Kopējie Darbības Izdevumi | 55.623 | 43.439 | 56.258 | 55.721 | 59.793 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 10.73 | 10.806 | 10.86 | 10.042 | 9.743 |
| Pētniecība un Attīstība | 44.893 | 32.633 | 45.398 | 45.679 | 50.05 |
| Darbības Izdevumi | -50.379 | -37.645 | -53.821 | -53.72 | -57.666 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -0.79 | -1.018 | -0.263 | -0.861 | 1.32 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Neto Ienākumi | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Atšķaidītie Neto Ienākumi | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
| Atšķaidītie Ienākumi par Akcijām | 26.376 | 26.362 | 26.338 | 26.323 | 26.243 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.93998 | -1.46662 | -2.05346 | -2.07351 | -2.14709 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.93998 | -1.46662 | -2.05346 | -2.07351 | -2.14709 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 378.961 | 467.789 | 74.29 | 41.828 | 50.868 |
| Nauda un Īstermiņa Ieguldījumi | 370.492 | 462.895 | 71.353 | 36.709 | 48.573 |
| Nauda un Ekvivalenti | 370.492 | 462.895 | 71.353 | 36.709 | 24.965 |
| Īstermiņa Ieguldījumi | 0 | 23.608 | |||
| Debitoru Parādu Kopsumma, Neto | 3.367 | 2.125 | 2.179 | 4.481 | 0.48 |
| Accounts Receivable - Trade, Net | 3.367 | 2.125 | 2.179 | 4.481 | 0.48 |
| Prepaid Expenses | 5.102 | 2.769 | 0.758 | 0.638 | 0.704 |
| Other Current Assets, Total | 0 | 1.111 | |||
| Total Assets | 392.814 | 476.456 | 82.143 | 44.198 | 52.024 |
| Property/Plant/Equipment, Total - Net | 11.261 | 8.56 | 7.483 | 1.975 | 1.049 |
| Property/Plant/Equipment, Total - Gross | 15.517 | 11.623 | 9.664 | 2.016 | |
| Accumulated Depreciation, Total | -4.256 | -3.063 | -2.181 | -0.967 | |
| Other Long Term Assets, Total | 2.077 | 0.107 | 0.107 | 0.107 | 0.107 |
| Total Current Liabilities | 99.537 | 49.521 | 21.324 | 12.577 | 11.04 |
| Accounts Payable | 10.058 | 10.774 | 5.793 | 2.398 | 1.79 |
| Accrued Expenses | 23.523 | 19.389 | 4.384 | 3.907 | 1.812 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 43.482 | 18.108 | 11.147 | 6.272 | 7.438 |
| Total Liabilities | 164.603 | 79.903 | 56.351 | 30.556 | 18.23 |
| Total Long Term Debt | 40.633 | 13.845 | 14.995 | 9.911 | 0 |
| Other Liabilities, Total | 24.433 | 16.537 | 20.032 | 8.068 | 7.19 |
| Total Equity | 228.211 | 396.553 | 25.792 | 13.642 | 33.794 |
| Common Stock | 0.026 | 0.026 | 0.015 | 0.214 | 0.212 |
| Additional Paid-In Capital | 575.675 | 540.343 | 97.445 | 58.302 | 56.674 |
| Retained Earnings (Accumulated Deficit) | -347.49 | -143.816 | -71.668 | -44.874 | -23.089 |
| Other Equity, Total | 0 | -0.003 | |||
| Total Liabilities & Shareholders’ Equity | 392.814 | 476.456 | 82.143 | 44.198 | 52.024 |
| Total Common Shares Outstanding | 26.372 | 26.192 | 15.138 | 10.719 | 10.656 |
| Long Term Investments | 0.515 | 0.263 | 0.288 | ||
| Long Term Debt | 40.633 | 13.845 | 14.995 | 9.911 | |
| Current Port. of LT Debt/Capital Leases | 22.474 | 1.25 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 327.005 | 378.961 | 420.966 | 438.038 | 469.996 |
| Nauda un Īstermiņa Ieguldījumi | 319.678 | 370.492 | 413.88 | 433.574 | 466.839 |
| Nauda un Ekvivalenti | 319.678 | 370.492 | 413.88 | 433.574 | 466.839 |
| Debitoru Parādu Kopsumma, Neto | 3.691 | 3.367 | 2.015 | 2.163 | 2.007 |
| Accounts Receivable - Trade, Net | 3.691 | 3.367 | 2.015 | 2.163 | 2.007 |
| Prepaid Expenses | 3.636 | 5.102 | 5.071 | 2.301 | 1.15 |
| Total Assets | 341.988 | 392.814 | 434.536 | 448.813 | 481.468 |
| Property/Plant/Equipment, Total - Net | 12.775 | 11.261 | 10.826 | 9.748 | 10.117 |
| Property/Plant/Equipment, Total - Gross | 17.255 | 15.517 | 14.772 | 13.405 | 13.487 |
| Accumulated Depreciation, Total | -4.48 | -4.256 | -3.946 | -3.657 | -3.37 |
| Long Term Investments | 0.131 | 0.515 | 0.67 | 0.92 | 1.248 |
| Other Long Term Assets, Total | 2.077 | 2.077 | 2.074 | 0.107 | 0.107 |
| Total Current Liabilities | 107.306 | 99.537 | 118.239 | 70.769 | 53.333 |
| Accounts Payable | 10.014 | 10.058 | 8.265 | 10.084 | 5.597 |
| Accrued Expenses | 19.97 | 23.523 | 33.876 | 37.614 | 26.675 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 24.26 | 22.474 | 18.482 | 5 | 3.125 |
| Other Current Liabilities, Total | 53.062 | 43.482 | 57.616 | 18.071 | 17.936 |
| Total Liabilities | 157.239 | 164.603 | 175.41 | 143.165 | 128.861 |
| Total Long Term Debt | 39.235 | 40.633 | 42.345 | 56.309 | 58.147 |
| Long Term Debt | 39.235 | 40.633 | 42.345 | 56.309 | 58.147 |
| Other Liabilities, Total | 10.698 | 24.433 | 14.826 | 16.087 | 17.381 |
| Total Equity | 184.749 | 228.211 | 259.126 | 305.648 | 352.607 |
| Common Stock | 0.026 | 0.026 | 0.026 | 0.026 | 0.026 |
| Additional Paid-In Capital | 583.382 | 575.675 | 567.927 | 560.365 | 552.743 |
| Retained Earnings (Accumulated Deficit) | -398.659 | -347.49 | -308.827 | -254.743 | -200.162 |
| Total Liabilities & Shareholders’ Equity | 341.988 | 392.814 | 434.536 | 448.813 | 481.468 |
| Total Common Shares Outstanding | 26.407 | 26.372 | 26.349 | 26.327 | 26.319 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
| Nauda no Darbības | -135.043 | -42.861 | -6.445 | -20.76 | -0.46 |
| Nauda no Darbības | 1.193 | 0.882 | 0.684 | 0.582 | 0.41 |
| Bezskaidras Naudas Preces | 36.205 | 7.189 | 2.88 | 1.599 | 2.668 |
| Izmaiņas Apgrozāmajā Kapitālā | 31.233 | 21.216 | 15.982 | -1.156 | 7.364 |
| Nauda no Ieguldījumu Darbībām | -3.406 | -1.742 | -0.818 | 22.134 | 10.355 |
| Kapitālie Izdevumi | -3.406 | -1.742 | -0.818 | -1.478 | -0.251 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 0 | 23.612 | 10.606 | ||
| Nauda no Darbībām ar Finansēšanu | 48.016 | 436.145 | 41.907 | 10.204 | 6.998 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 1.417 | 436.145 | 36.962 | 0.332 | 1.348 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 46.599 | 0 | 4.945 | 9.872 | 5.65 |
| Neto Izmaiņas Naudā | -90.433 | 391.542 | 34.644 | 11.578 | 16.893 |
| Samaksātie Procenti Naudā | 0.684 | 0.751 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -51.169 | -203.674 | -165.011 | -110.927 | -56.346 |
| Cash From Operating Activities | -49.039 | -135.043 | -92.546 | -75.893 | -42.95 |
| Cash From Operating Activities | 0.224 | 1.193 | 0.883 | 0.594 | 0.307 |
| Non-Cash Items | 8.516 | 36.205 | 27.281 | 19.773 | 10.995 |
| Cash Interest Paid | 0.169 | 0.684 | 0.173 | 0.173 | 0.169 |
| Changes in Working Capital | -6.61 | 31.233 | 44.301 | 14.667 | 2.094 |
| Cash From Investing Activities | -2.111 | -3.406 | -2.288 | -0.522 | -0.118 |
| Capital Expenditures | -2.111 | -3.406 | -2.288 | -0.522 | -0.118 |
| Cash From Financing Activities | 0.336 | 48.016 | 47.786 | 47.094 | 47.012 |
| Issuance (Retirement) of Stock, Net | 0.336 | 1.417 | 1.187 | 0.495 | 0.413 |
| Issuance (Retirement) of Debt, Net | 0 | 46.599 | 46.599 | 46.599 | 46.599 |
| Net Change in Cash | -50.814 | -90.433 | -47.048 | -29.321 | 3.944 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 16.0026 | 4239554 | 672057 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 8.5225 | 2257846 | -472616 | 2022-12-31 | LOW |
| ARK Investment Management LLC | Investment Advisor | 7.5961 | 2012429 | -169274 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2255 | 1649315 | 32754 | 2022-12-31 | LOW |
| Payne (Joseph E) | Individual Investor | 5.5868 | 1480097 | 5000 | 2022-11-23 | LOW |
| Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 5.4696 | 1449060 | -10355 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.4637 | 1447503 | 113607 | 2022-12-31 | LOW |
| Ultragenyx Pharmaceutical Inc | Corporation | 4.5295 | 1200000 | -200000 | 2021-10-25 | LOW |
| Balyasny Asset Management LP | Hedge Fund | 3.7906 | 1004235 | 664852 | 2022-12-31 | HIGH |
| Fidelity Management & Research Company LLC | Investment Advisor | 3.4358 | 910243 | -44082 | 2022-12-31 | LOW |
| Woodline Partners LP | Hedge Fund | 2.8397 | 752331 | -125193 | 2022-12-31 | HIGH |
| BofA Global Research (US) | Research Firm | 2.5892 | 685954 | 577968 | 2022-12-31 | LOW |
| Chivukula (Padmanabh) | Individual Investor | 2.2249 | 589448 | -5000 | 2023-03-06 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6983 | 449939 | 33148 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.2402 | 328567 | -2938 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.1449 | 303306 | 112903 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1432 | 302861 | 159743 | 2022-12-31 | LOW |
| Sassine (Andy H) | Individual Investor | 1.0354 | 274313 | 1068 | 2022-08-15 | LOW |
| Goldman Sachs & Company, Inc. | Research Firm | 0.9932 | 263138 | -35493 | 2022-12-31 | MED |
| Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 0.7899 | 209254 | -51726 | 2022-12-31 | MED |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Arcturus Therapeutics Holdings Inc. Company profile
Par Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. ir vēlu stadijā esošs globāls klīnisks uzņēmums, kas nodarbojas ar vēstnešu ribonukleīnskābes (mRNA) zāļu ražošanu. Uzņēmums koncentrējas uz infekcijas slimību vakcīnu izstrādi un nozīmīgām iespējām aknu un elpošanas sistēmas reto slimību jomā. Papildus mRNS platformai uzņēmuma lipīdu nanodaļiņu (LNP) piegādes sistēmai LUNAR ir potenciāls, lai nodrošinātu vairāku nukleīnskābju medikamentu lietošanu, un tā pašpastiprinošajai mRNS tehnoloģijai (Self-Transcribing and Replicating RNA (STARR), tehnoloģija) ir potenciāls, lai nodrošinātu ilglaicīgāku RNS un ilgstošu proteīna ekspresiju pie zemākām devām. Uzņēmuma izstrādes stadijā esošie produkti, kuros izmantota STARR tehnoloģija, ir ARCT-021, ARCT-154 un ARCT-165. Uzņēmuma COVID-19 vakcīnas kandidāts ARCT-021, kas balstīts uz STARR tehnoloģijas platformu, ir II fāzes klīnisko izmēģinājumu stadijā. Tās LUNAR-FLU vakcīna sastāv no aknu franšīzes ARCT-810 (LUNAR-OTC) un plaušu franšīzes ARCT-032 (LUNAR-CF).
| Industry: | Biotechnology & Medical Research (NEC) |
10628 Science Center Dr Ste 250
SAN DIEGO
CALIFORNIA 92121-1132
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com